TABLE 1.

Anaplastic EPN PFA patient demographics, dates of primary tissue diagnosis, clinical outcome, IHC, and FISH data

Case	Infant	Sex	Age at diagnosis	Clinical details	p16		+1q	MIB-1(%)
					IHC	FISH
1	Yes	M	10 months	DOD after 23 months, GTR, XRT and lapatinib, one recurrence	Weak	Normal	Normal	37
2	Yes	M	8 months	DOD after 48 months, GTR, XRT, multiple recurrences	Weak	Normal	Normal	59
3	Yes	F	7 months	DOD after 33 months, GTR, XRT, multiple recurrences, chemo	Negative	LOH	Normal	54
4	Yes	F	6 months	DOD after 98 months, GTR, XRT, two recurrences	Negative	Normal	Normal	51
5	Yes	M	11 months	Living after 11 months, GTR, XRT, chemo	Negative	LOH	Normal	40
6	Yes	M	4 months	DOD after 4 months, STR, oral palliative etoposide	Weak	–	–	75
7	No	F	31 months	Living after 13 years, STR, XRT, chemo	Weak	–	–	36
8	No	M	37 months	Living after 9 years, GTR, XRT, chemo	Weak	Normal	Normal	32
9	No	M	45 months	Living after 4 years, GTR, XRT, chemo, multiple recurrences	Moderate	Normal	Gain	30
10	No	F	22 months	Living after 5 years, GTR, XRT, chemo, single recurrence	Moderate	Normal	Normal	13
11	No	M	32 months	Living after 15 years, GTR, XRT, chemo, multiple recurrences	Moderate	Normal	Normal	47
12	No	M	72 months	DOD after 17 months, STR, XRT, chemo, drop metastases	Moderate	–	Gain	45
13	No	M	204 months	Living after 5 years, STR, XRT, chemo, drop metastasis	Moderate	–	Gain	35

Chemo, protocol chemotherapy regimen; DOD, died of disease; GTR, gross total resection; LOH, loss of heterozygosity; STR, subtotal resection; XRT, radiation therapy; “–”, used when data are not available.